Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) is expected to release its earnings data before the market opens on Tuesday, February 11th. Analysts expect Bicara Therapeutics to post earnings of ($0.31) per share for the quarter.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, analysts expect Bicara Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $12.13 on Monday. The firm has a 50-day moving average of $15.66. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright boosted their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Wedbush began coverage on Bicara Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $31.00 target price on the stock. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, Rodman & Renshaw assumed coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Buy” and an average target price of $41.20.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.